Peroral endoscopic myotomy: is it better to perform it in naive patients or as second-line therapy? Results of an open-label-controlled study in 105 patients.


Journal

Surgical endoscopy
ISSN: 1432-2218
Titre abrégé: Surg Endosc
Pays: Germany
ID NLM: 8806653

Informations de publication

Date de publication:
05 2023
Historique:
received: 04 11 2020
accepted: 09 10 2021
medline: 5 5 2023
pubmed: 21 1 2023
entrez: 20 1 2023
Statut: ppublish

Résumé

Whether Peroral Endoscopic Myotomy (POEM) can be proposed as a second-line treatment in patients with achalasia remains to be confirmed in real-life series. This study aimed to compare the efficacy, feasibility and safety of POEM between treatment-naïve patients and patients who had prior endoscopic or surgical therapies for achalasia. All consecutive patients who underwent a POEM procedure for achalasia in our centre from June 2015 to September 2018 were included in this retrospective study. They were classified into treatment-naïve patients (POEM1) and patients who had at least one previous endoscopic and/or surgical treatment for achalasia (POEM2). A total of 105 patients were included, 52 in the POEM1 group and 53 in the POEM2 group. Clinical success (defined as an Eckardt score ≤ 3) at 6 months was observed in 93% of POEM1 patients and 84% of POEM2 patients (p = 0.18). Technical success rate was not significantly different between the two groups (100% vs 96%, respectively; p = 0.50). No significant difference was noted in terms of adverse event rate (19% vs 19%, respectively; p = 1.00). Post-procedure pain occurred in 12% of treatment-naive and 9% of non-naïve patients (p = 0.76). The median length of hospital stay was 3 days in both groups (p = 0.17). Symptomatic gastroesophageal reflux occurred in 25% of POEM1 patients and 16% of POEM2 patients (p = 0.24). Efficacy, feasibility and safety of POEM are not different between treatment-naïve and non-naïve patients. POEM is a valuable second-line approach in patients with persistent symptoms of achalasia after surgical or endoscopic treatments.

Sections du résumé

BACKGROUND
Whether Peroral Endoscopic Myotomy (POEM) can be proposed as a second-line treatment in patients with achalasia remains to be confirmed in real-life series.
OBJECTIVE
This study aimed to compare the efficacy, feasibility and safety of POEM between treatment-naïve patients and patients who had prior endoscopic or surgical therapies for achalasia.
METHODS
All consecutive patients who underwent a POEM procedure for achalasia in our centre from June 2015 to September 2018 were included in this retrospective study. They were classified into treatment-naïve patients (POEM1) and patients who had at least one previous endoscopic and/or surgical treatment for achalasia (POEM2).
RESULTS
A total of 105 patients were included, 52 in the POEM1 group and 53 in the POEM2 group. Clinical success (defined as an Eckardt score ≤ 3) at 6 months was observed in 93% of POEM1 patients and 84% of POEM2 patients (p = 0.18). Technical success rate was not significantly different between the two groups (100% vs 96%, respectively; p = 0.50). No significant difference was noted in terms of adverse event rate (19% vs 19%, respectively; p = 1.00). Post-procedure pain occurred in 12% of treatment-naive and 9% of non-naïve patients (p = 0.76). The median length of hospital stay was 3 days in both groups (p = 0.17). Symptomatic gastroesophageal reflux occurred in 25% of POEM1 patients and 16% of POEM2 patients (p = 0.24).
CONCLUSION
Efficacy, feasibility and safety of POEM are not different between treatment-naïve and non-naïve patients. POEM is a valuable second-line approach in patients with persistent symptoms of achalasia after surgical or endoscopic treatments.

Identifiants

pubmed: 36670217
doi: 10.1007/s00464-021-08767-6
pii: 10.1007/s00464-021-08767-6
pmc: PMC10156842
doi:

Types de publication

Controlled Clinical Trial Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3760-3768

Informations de copyright

© 2023. The Author(s).

Références

J Gastrointest Surg. 2013 Jul;17(7):1188-92
pubmed: 23609138
Clin Gastroenterol Hepatol. 2018 Sep;16(9):1420-1426.e2
pubmed: 29208537
Gastrointest Endosc. 2010 Mar;71(3):446-54
pubmed: 20189503
Br J Surg. 2019 Mar;106(4):332-341
pubmed: 30690706
Endoscopy. 2010 Apr;42(4):265-71
pubmed: 20354937
Endosc Int Open. 2016 May;4(5):E577-82
pubmed: 27227118
Gastrointest Endosc. 2017 Jun;85(6):1208-1211
pubmed: 27756611
Dig Endosc. 2020 Nov;32(7):1042-1049
pubmed: 32012360
Lancet. 2014 Jan 4;383(9911):83-93
pubmed: 23871090
Am J Gastroenterol. 2013 Jul;108(7):1076-81
pubmed: 23458850
Neurogastroenterol Motil. 2015 Feb;27(2):160-74
pubmed: 25469569
Gastrointest Endosc. 2020 Feb;91(2):213-227.e6
pubmed: 31839408
J Am Coll Surg. 2015 Aug;221(2):256-64
pubmed: 26206634
N Engl J Med. 2011 May 12;364(19):1807-16
pubmed: 21561346
Neurogastroenterol Motil. 2014 Sep;26(9):1248-55
pubmed: 24916630
J Am Coll Surg. 2013 Apr;216(4):736-43; discussion 743-4
pubmed: 23415553
United European Gastroenterol J. 2020 Feb;8(1):13-33
pubmed: 32213062
Ann Surg. 2018 Mar;267(3):451-460
pubmed: 28549006
Surg Endosc. 2018 Jan;32(1):421-427
pubmed: 28664434
Gastroenterology. 2013 Apr;144(4):718-25; quiz e13-4
pubmed: 23277105
Gut. 2016 May;65(5):732-9
pubmed: 26614104
Endoscopy. 2018 Apr;50(4):358-370
pubmed: 29169196
Am Surg. 2011 Mar;77(3):330-6
pubmed: 21375846
J Gastroenterol Hepatol. 2014 Aug;29(8):1609-13
pubmed: 24628480
Surg Endosc. 2017 Jun;31(6):2596-2601
pubmed: 27699518
Endoscopy. 2017 Feb;49(2):191-198
pubmed: 28122386
Gastroenterology. 1992 Dec;103(6):1732-8
pubmed: 1451966
Surg Endosc. 2016 Nov;30(11):4817-4826
pubmed: 26932548
Surg Endosc. 2015 May;29(5):1064-70
pubmed: 25249143
JAMA. 2019 Jul 9;322(2):134-144
pubmed: 31287522
Ann Surg. 2016 Jan;263(1):82-7
pubmed: 25361224
Surg Endosc. 2017 Apr;31(4):1841-1848
pubmed: 27553792
Indian J Anaesth. 2011 Mar;55(2):111-5
pubmed: 21712864
Endoscopy. 2013;45(3):161-6
pubmed: 23389963
Endoscopy. 2016 Dec;48(12):1059-1068
pubmed: 27617421
Gastroenterology. 2013 Aug;145(2):309-11.e1-3
pubmed: 23665071
Gastrointest Endosc. 2018 Apr;87(4):956-961
pubmed: 28235595
Am J Gastroenterol. 2017 Aug;112(8):1267-1276
pubmed: 28534521
Ann Surg. 2016 Sep;264(3):508-17
pubmed: 27513156

Auteurs

Raphael Olivier (R)

Service de Gastroentérologie, CHU de Poitiers, Poitiers, France.
Institut des Maladies de l'Appareil Digestif, IMAD, CHU Nantes, Hôpital Hôtel-Dieu, 1 place Ricordeau, 44093, Nantes cedex, France.

Charlène Brochard (C)

Service des Maladies de l'Appareil Digestif, CHU Pontchaillou, Université de Rennes 1, Rennes, France.
Service d'Explorations Fonctionnelles Digestives, CHU Pontchaillou, Université de Rennes 1, Rennes, France.
CIC 1414, INPHY, Université de Rennes 1, Rennes, France.

Stanislas Bruley des Varannes (SB)

Institut des Maladies de l'Appareil Digestif, IMAD, CHU Nantes, Hôpital Hôtel-Dieu, 1 place Ricordeau, 44093, Nantes cedex, France.

Alain Ropert (A)

Service des Maladies de l'Appareil Digestif, CHU Pontchaillou, Université de Rennes 1, Rennes, France.
Service d'Explorations Fonctionnelles Digestives, CHU Pontchaillou, Université de Rennes 1, Rennes, France.

Timothée Wallenhorst (T)

Service des Maladies de l'Appareil Digestif, CHU Pontchaillou, Université de Rennes 1, Rennes, France.

Noémi Reboux (N)

Service de Gastroentérologie, CHRU de Brest, Brest, France.

Lucille Quénéhervé (L)

Institut des Maladies de l'Appareil Digestif, IMAD, CHU Nantes, Hôpital Hôtel-Dieu, 1 place Ricordeau, 44093, Nantes cedex, France.
Service de Gastroentérologie, CHRU de Brest, Brest, France.

Emmanuel Coron (E)

Institut des Maladies de l'Appareil Digestif, IMAD, CHU Nantes, Hôpital Hôtel-Dieu, 1 place Ricordeau, 44093, Nantes cedex, France. eemmanuel.coron@hcuge.ch.
Department of Gastroenterology and Hepatology, University Hospital of Geneva (HUG), rue Gabrielle Perret- Gentil 4, Genève, 1205-1211, Switzerland. eemmanuel.coron@hcuge.ch.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH